Cetilistat moves to Phase III in Japan
This article was originally published in Scrip
Takedahas begun the Japanese Phase III development of Alizyme's pancreatic lipase inhibitor cetilistat (ATL-962). The formal start of the programme has triggered a $3 million milestone payment to the UK firm, which has now received $10 million under the licensing agreement and could receive up to a further $32 million before sales royalties. Takeda holds exclusive local rights for use in obesity and related disorders such as type 2 diabetes and dyslipidaemia and has already completed a Phase II trial in around 450 diabetic obese patients. This showed weight loss, glycaemic control and other benefits for cetilistat compared with placebo over a six-month treatment period.